That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

One of them, called APOE4, has been linked to a much higher risk of developing Alzheimer's disease, and carriers often have ...

NEW DELHI: A team of scientists has found that the presence of the APOE4 protein -- the most important genetic risk factor for Alzheimer's disease -- can cause healthy immune cells in the brain -- ...

Using cerebrospinal fluid from living patients, researchers have identified specific proteins and genetic pathways involved ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

The EMA has changed its mind about an earlier decision that the risks of Leqembi (lecanemab) outweigh the benefits and is now recommending the Alzheimer’s disease drug ... to 274 patients with two ...

After re-examining its initial opinion, EMA’s human medicines committee, or CHMP, has recommended granting a marketing authorisation to Leqembi for treating mild cognitive impairment or mild dementia ...

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai - ...